A
Anand Devaraj
Researcher at National Institutes of Health
Publications - 166
Citations - 7845
Anand Devaraj is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Medicine & Lung cancer. The author has an hindex of 33, co-authored 123 publications receiving 5136 citations. Previous affiliations of Anand Devaraj include Imperial College London & National Health Service.
Papers
More filters
Journal ArticleDOI
Defining the road map to a UK national lung cancer screening programme.
Emma O'Dowd,Richard W J Lee,Ahsan R. Akram,Emily C. Bartlett,Stephen H Bradley,Katherine Emma Brain,Matthew E.J. Callister,Anand Devaraj,Sinan R. Eccles,John K. Field,J. Fox,Seamus Grundy,Sam M. Janes,Martin Ledson,Melanie Mackean,Anne Mackie,Kieran McManus,Rachael L Murray,Arjun Nair,Samantha L Quaife,Robert C. Rintoul,Anne M Stevenson,Yvonne Summers,Louise S. Wilkinson,Richard Booton,David R Baldwin,Phil Crosbie +26 more
TL;DR: The UK has been world leading in addressing logistical issues with lung cancer screening through clinical trials, implementation pilots, and the National Health Service (NHS) England Targeted Lung Health Check Programme as mentioned in this paper .
Proceedings ArticleDOI
Novel CT markers of volume loss in idiopathic pulmonary fibrosis (IPF) predict mortality
Hasti Robbie,Athol U. Wells,Joseph Jacob,Simon L.F. Walsh,Arjun Nair,Priscilla Tazoniero,Ahgasthikan Srikanthan,Angela Atinga,Rose Camoras,Anand Devaraj +9 more
Journal ArticleDOI
Hypoxia and eosinophilia in a patient with difficult asthma.
Journal ArticleDOI
Diffuse granulomatous disease: looking inside and outside the lungs
TL;DR: The Kco, at nearly twice the TLco in %-predicted terms, indicated a low likelihood of major pulmonary vasculopathy and the absence of airflow limitation or small airway dysfunction steered the diagnosis away from primary bronchiolar disorders.
Journal ArticleDOI
Quantitative 18F-fluorodeoxyglucose positron emission tomography/computed tomography to assess pulmonary inflammation in COPD.
Laurence Vass,Marie Fisk,Joseph Cheriyan,Joseph Cheriyan,Divya Mohan,Julia R. Forman,Adelola Oseni,Anand Devaraj,Kaisa M. Mäki-Petäjä,Carmel M. McEniery,Jonathan Fuld,Nicholas S Hopkinson,David A. Lomas,John R. Cockcroft,Ruth Tal-Singer,Michael I. Polkey,Ian B. Wilkinson +16 more
TL;DR: F-Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) imaging may improve knowledge of pulmonary inflammation in COPD patients and aid early development of novel therapies as an imaging biomarker.